BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frisk P, Aggefors K, Cars T, Feltelius N, Loov SA, Wettermark B, Weiland O. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol 2018;74:971-8. [PMID: 29632961 DOI: 10.1007/s00228-018-2456-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Pisana A, Wettermark B, Kurdi A, Tubic B, Pontes C, Zara C, Van Ganse E, Petrova G, Mardare I, Fürst J, Roig-izquierdo M, Melien O, Bonanno PV, Banzi R, Marković-peković V, Mitkova Z, Godman B. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. Front Pharmacol 2022;13:873556. [DOI: 10.3389/fphar.2022.873556] [Reference Citation Analysis]
2 Faleiros DR, Nunes da Silva E, Santos AC, Godman BB, Goncalves Pereira R, Guerra Junior AA. Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions. Expert Rev Pharmacoecon Outcomes Res 2022;:1-13. [PMID: 35320682 DOI: 10.1080/14737167.2022.2057950] [Reference Citation Analysis]
3 Lindgren P, Löfvendahl S, Brådvik G, Weiland O, Jönsson B. Value appropriation in hepatitis C. Eur J Health Econ 2021. [PMID: 34855072 DOI: 10.1007/s10198-021-01409-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Godman B, Fadare J, Kwon HY, Dias CZ, Kurdi A, Dias Godói IP, Kibuule D, Hoxha I, Opanga S, Saleem Z, Bochenek T, Marković-Peković V, Mardare I, Kalungia AC, Campbell S, Allocati E, Pisana A, Martin AP, Meyer JC. Evidence-based public policy making for medicines across countries: findings and implications for the future. J Comp Eff Res 2021;10:1019-52. [PMID: 34241546 DOI: 10.2217/cer-2020-0273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
5 Faleiros DR, Alvares-Teodoro J, Nunes da Silva E, Godman BB, Gonçalves Pereira R, Gurgel Andrade EI, de Assis Acurcio FA, Guerra Júnior AA. Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33971778 DOI: 10.1080/14737167.2021.1927716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lybeck C, Bruce D, Montgomery SM, Aleman S, Duberg A. Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct‐acting antivirals. GastroHep 2021;3:185-95. [DOI: 10.1002/ygh2.456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampirolli Dias C, Martin AP, Oortwijn W, Timoney A, Gustafsson LL, Voncina L, Kwon HY, Gulbinovic J, Gotham D, Wale J, Cristina Da Silva W, Bochenek T, Allocati E, Kurdi A, Ogunleye OO, Meyer JC, Hoxha I, Malaj A, Hierländer C, Sauermann R, Hamelinck W, Petrova G, Laius O, Langner I, Yfantopoulos J, Joppi R, Jakupi A, Greiciute-Kuprijanov I, Vella Bonanno P, Piepenbrink JH, de Valk V, Wladysiuk M, Marković-Peković V, Mardare I, Fürst J, Tomek D, Obach Cortadellas M, Zara C, Pontes C, McTaggart S, Laba TL, Melien Ø, Wong-Rieger D, Bae S, Hill R. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res 2021;21:527-40. [PMID: 33535841 DOI: 10.1080/14737167.2021.1884546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol 2021;14:95-103. [PMID: 33252992 DOI: 10.1080/17512433.2021.1856655] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
9 Li C, Liang J, Xiang H, Chen H, Tian J. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore) 2020;99:e23384. [PMID: 33235113 DOI: 10.1097/MD.0000000000023384] [Reference Citation Analysis]
10 Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Appl Health Econ Health Policy 2020;18:5-16. [PMID: 31696433 DOI: 10.1007/s40258-019-00527-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
11 Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. Journal of Medical Economics 2020;23:1209-14. [DOI: 10.1080/13696998.2020.1824161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lindgren P, Löfvendahl S, Brådvik G, Weiland O. Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals. J Viral Hepat 2021;28:142-6. [PMID: 32896927 DOI: 10.1111/jvh.13398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Økland JM, Leiva RAM, Vickerman P, Johansson KA, Fadnes LT. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open 2020;10:e036355. [PMID: 32847908 DOI: 10.1136/bmjopen-2019-036355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics 2020;38:1165-85. [PMID: 32734573 DOI: 10.1007/s40273-020-00943-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
15 Eriksson I, von Euler M, Malmström RE, Godman B, Wettermark B. Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System. Appl Health Econ Health Policy 2019;17:93-101. [PMID: 30284150 DOI: 10.1007/s40258-018-0434-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Linnér L, Eriksson I, Persson M, Wettermark B. Forecasting drug utilization and expenditure: ten years of experience in Stockholm. BMC Health Serv Res 2020;20:410. [PMID: 32393238 DOI: 10.1186/s12913-020-05170-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Gad M, Salem A, Oortwijn W, Hill R, Godman B. Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions. Front Pharmacol 2020;11:144. [PMID: 32194401 DOI: 10.3389/fphar.2020.00144] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
18 Artime E, Qizilbash N, Garrido-estepa M, Vora P, Soriano-gabarró M, Asiimwe A, Pocock S. Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opinion on Drug Safety 2019;18:443-54. [DOI: 10.1080/14740338.2019.1612875] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Vella Bonanno P, Bucsics A, Simoens S, Martin AP, Oortwijn W, Gulbinovič J, Rothe C, Timoney A, Ferrario A, Gad M, Salem A, Hoxha I, Sauermann R, Kamusheva M, Dimitrova M, Petrova G, Laius O, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Jakupi A, Bochenek T, Wladysiuk M, Furtado C, Marković-Peković V, Mardare I, Meshkov D, Fürst J, Tomek D, Cortadellas MO, Zara C, Haycox A, Campbell S, Godman B. Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. Expert Rev Pharmacoecon Outcomes Res 2019;19:251-61. [PMID: 30696372 DOI: 10.1080/14737167.2019.1575730] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
20 Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S, Kurdi A, Gad M, Gulbinovič J, Timoney A, Bochenek T, Salem A, Hoxha I, Sauermann R, Massele A, Guerra AA Jr, Petrova G, Mitkova Z, Achniotou G, Laius O, Sermet C, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Oluka M, Kwon HY, Jakupi A, Kalemeera F, Fadare JO, Melien O, Pomorski M, Wladysiuk M, Marković-Peković V, Mardare I, Meshkov D, Novakovic T, Fürst J, Tomek D, Zara C, Diogene E, Meyer JC, Malmström R, Wettermark B, Matsebula Z, Campbell S, Haycox A. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Front Public Health 2018;6:328. [PMID: 30568938 DOI: 10.3389/fpubh.2018.00328] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 14.5] [Reference Citation Analysis]